GLOBALPHARMA TO MARKET ETHYPHARM'S ALLERGY DRUG IN GCC REGION

Ethypharm India has signed an out-licensing and supply contract with Dubai-based Globalpharma to market 10-mg cetirizine tablets in the Gulf Cooperation Council (GCC) region -- an area that encompasses Saudi Arabia, Bahrain, Kuwait, Oman, Qatar and the United Arab Emirates.

Under the terms of the agreement, Ethypharm will be responsible for the development of orally disintegrating cetirizine tablets. The product will be supplied by Ethypharm's manufacturing facility near Mumbai, and Globalpharma will be responsible for marketing and distribution in GCC markets.

Cetirizine is mainly indicated for allergic rhinitis, urticaria (an allergic skin condition) and symptoms of hypersensitivity reactions.